GALDERMA Committed to the future of Dermatology Read more ...
Talent Working at GaldermaRead more ...
FOCUSED Patients at the heart of everything we doRead more ...
PARTNER With Healthcare Professionals around the WorldRead more ...
You are here » News
Lausanne, Switzerland – July 16, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, announced today that Japan’s Ministry of Health, Labor and Welfare has approved Differin® Gel 0.1% (adapalene), a novel topical treatment for acne vulgaris in Japan. The drug will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi.
Read more...
Posted in: Press release
Lausanne, Switzerland – April 11, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its acquisition of CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI). As a result of the transaction, CollaGenex has become a wholly owned subsidiary of Galderma Laboratories.
Lausanne, Switzerland – April 7, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its all cash tender offer for CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI). The tender offer expired at 12:00 Midnight, New York City time, at the end of Friday, April 4, 2008.
Lausanne Switzerland, 7 March, 2008 – Galderma Pharma, S.A. announces an agreement with ZARS Pharma, Inc. giving Galderma exclusive rights for all markets outside the USA and Canada for promotion and distribution of a novel topical anesthetic cream. This partnership follows an agreement signed last year between Galderma and ZARS Pharma for the promotion and distribution of Pliaglis™ in the USA and Canada.
Lausanne, Switzerland and Newtown, PA – February 26, 2008 Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI) today announced a definitive agreement pursuant to which Galderma’s U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex. The transaction was unanimously approved by the boards of directors of Galderma and CollaGenex.
Follow us
Growing a responsible dermatological community
Discover some of the positive initiatives we are involved in across the world
We are committed
